Compare VRAX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 31.9M |
| IPO Year | 2021 | 2020 |
| Metric | VRAX | EVAX |
|---|---|---|
| Price | $0.14 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 6.0M | 29.9K |
| Earning Date | 03-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.20 |
| 52 Week High | $1.34 | $12.15 |
| Indicator | VRAX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 49.43 |
| Support Level | N/A | $2.70 |
| Resistance Level | $0.25 | $4.64 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 5.87 | 47.38 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.